232 related articles for article (PubMed ID: 26108357)
21. Determination of the UGT1A1 polymorphism as guidance for irinotecan dose escalation in metastatic colorectal cancer treated with first-line bevacizumab and FOLFIRI (PURE FIST).
Tsai HL; Huang CW; Lin YW; Wang JH; Wu CC; Sung YC; Chen TL; Wang HM; Tang HC; Chen JB; Ke TW; Tsai CS; Huang HY; Wang JY
Eur J Cancer; 2020 Oct; 138():19-29. PubMed ID: 32829105
[TBL] [Abstract][Full Text] [Related]
22. DEK is a potential marker for aggressive phenotype and irinotecan-based therapy response in metastatic colorectal cancer.
Martinez-Useros J; Rodriguez-Remirez M; Borrero-Palacios A; Moreno I; Cebrian A; Gomez del Pulgar T; del Puerto-Nevado L; Vega-Bravo R; Puime-Otin A; Perez N; Zazo S; Senin C; Fernandez-Aceñero MJ; Soengas MS; Rojo F; Garcia-Foncillas J
BMC Cancer; 2014 Dec; 14():965. PubMed ID: 25515240
[TBL] [Abstract][Full Text] [Related]
23. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
[TBL] [Abstract][Full Text] [Related]
24. The value of genetic polymorphisms to predict toxicity in metastatic colorectal patients with irinotecan-based regimens.
Lamas MJ; Duran G; Balboa E; Bernardez B; Candamio S; Vidal Y; Mosquera A; Giraldez JM; Lopez R; Carracedo A; Barros F
Cancer Chemother Pharmacol; 2012 Jun; 69(6):1591-9. PubMed ID: 22535333
[TBL] [Abstract][Full Text] [Related]
25. Irinotecan hydrochloride.
Wilkinson K
Clin J Oncol Nurs; 2001; 5(4):179-80, 184. PubMed ID: 12690622
[No Abstract] [Full Text] [Related]
26. UDP-glucuronosyltransferase (UGT) 1A1*28 polymorphism-directed phase II study of irinotecan with 5'-deoxy-5-fluorouridine (5'-DFUR) for metastatic colorectal cancer.
Kanekiyo S; Hazama S; Kondo H; Nagashima A; Eto R; Yoshida S; Shimizu R; Araki A; Yamamoto T; Uchiyama T; Yoshino S; Okayama N; Hinoda Y; Oka M
Anticancer Res; 2013 Aug; 33(8):3423-30. PubMed ID: 23898114
[TBL] [Abstract][Full Text] [Related]
27. Mutations in DNA Repair Genes and Clinical Outcomes of Patients With Metastatic Colorectal Cancer Receiving Oxaliplatin or Irinotecan-containing Regimens.
Marks EI; Matera R; Olszewski AJ; Yakirevich E; El-Deiry WS; Safran H; Carneiro BA
Am J Clin Oncol; 2021 Feb; 44(2):68-73. PubMed ID: 33298767
[TBL] [Abstract][Full Text] [Related]
28. [Irinotecan in colorectal cancer].
Pozzo C; Cassano A; Barone C
Tumori; 2001; 87(1 Suppl 1):S49-50. PubMed ID: 11300023
[No Abstract] [Full Text] [Related]
29. The role of irinotecan in colorectal cancer.
Saltz LB
Curr Oncol Rep; 1999; 1(2):155-60. PubMed ID: 11122813
[TBL] [Abstract][Full Text] [Related]
30. Irinotecan. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
Wiseman LR; Markham A
Drugs; 1996 Oct; 52(4):606-23. PubMed ID: 8891470
[TBL] [Abstract][Full Text] [Related]
31. Phase III comparison of two irinotecan dosing regimens in second-line therapy of metastatic colorectal cancer.
Fuchs CS; Moore MR; Harker G; Villa L; Rinaldi D; Hecht JR
J Clin Oncol; 2003 Mar; 21(5):807-14. PubMed ID: 12610178
[TBL] [Abstract][Full Text] [Related]
32. UGT1A1*1/*28 and *1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer.
Sunakawa Y; Ichikawa W; Fujita K; Nagashima F; Ishida H; Yamashita K; Mizuno K; Miwa K; Kawara K; Akiyama Y; Araki K; Yamamoto W; Miya T; Narabayashi M; Ando Y; Hirose T; Saji S; Sasaki Y
Cancer Chemother Pharmacol; 2011 Aug; 68(2):279-84. PubMed ID: 20957480
[TBL] [Abstract][Full Text] [Related]
33. Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated According to Uridine Diphosphate Glucuronosyltransferase 1A1 Genotyping in Patients With Metastatic Colorectal Cancer.
Ma CJ; Huang CW; Yeh YS; Tsai HL; Hu HM; Wu IC; Cheng TL; Wang JY
Oncol Res; 2017 May; 25(5):673-679. PubMed ID: 27938508
[TBL] [Abstract][Full Text] [Related]
34. The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models.
Na YS; Jung KA; Kim SM; Hong YS; Ryu MH; Jang SJ; Moon DH; Cho DH; Kim JC; Lee JS; Kim TW
Cancer Chemother Pharmacol; 2011 Aug; 68(2):389-98. PubMed ID: 21046105
[TBL] [Abstract][Full Text] [Related]
35. [Recent results of irinotecan therapy in colorectal cancer].
Láng I; Hitre E
Magy Onkol; 2004; 48(4):281-8. PubMed ID: 15655572
[TBL] [Abstract][Full Text] [Related]
36. In vivo bioassay to detect irinotecan-stabilized DNA/topoisomerase I complexes in rats.
Barth SW; Briviba K; Watzl B; Jäger N; Marko D; Esselen M
Biotechnol J; 2010 Mar; 5(3):321-7. PubMed ID: 20213647
[TBL] [Abstract][Full Text] [Related]
37. Prophylaxis of irinotecan-induced diarrhea with neomycin and potential role for UGT1A1*28 genotype screening: a double-blind, randomized, placebo-controlled study.
de Jong FA; Kehrer DF; Mathijssen RH; Creemers GJ; de Bruijn P; van Schaik RH; Planting AS; van der Gaast A; Eskens FA; Janssen JT; Ruit JB; Verweij J; Sparreboom A; de Jonge MJ
Oncologist; 2006 Sep; 11(8):944-54. PubMed ID: 16951398
[TBL] [Abstract][Full Text] [Related]
38. RNA-seq reveals determinants for irinotecan sensitivity/resistance in colorectal cancer cell lines.
Li XX; Zheng HT; Peng JJ; Huang LY; Shi DB; Liang L; Cai SJ
Int J Clin Exp Pathol; 2014; 7(5):2729-36. PubMed ID: 24966994
[TBL] [Abstract][Full Text] [Related]
39. Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer.
Lampropoulou DI; Aravantinos G; Katifelis H; Lazaris F; Laschos K; Theodosopoulos T; Papadimitriou C; Gazouli M
Cancer Biomark; 2019; 25(2):213-221. PubMed ID: 31045514
[TBL] [Abstract][Full Text] [Related]
40. Severe irinotecan-induced toxicities in a patient with uridine diphosphate glucuronosyltransferase 1A1 polymorphism.
Mehra R; Murren J; Chung G; Smith B; Psyrri A
Clin Colorectal Cancer; 2005 May; 5(1):61-4. PubMed ID: 15929808
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
